AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03511001 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: E-Cigarette Vs. Smoking as Usual
Description: 6 weeks of JUUL e-cigarettes vs. 6 weeks of smoking as usual
Study NCT02471313 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [18F] FMISO
Description: \[18F\] Fluromisonidazole, 1 h-(3-\[18F\]-fluro-2hydroxyl-propy10-2-nitro-imidazaole is an investigational positron emission tomography (PET) radiopharmaceutical for injection and used to visualize hypoxia imaging agent. Each patient will receive up to 10 mCi of \[18F\] FMISO PET imaging post TACE procedure.
Study NCT02706925 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 443651
Study NCT02706925 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT00600067 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Phentermine/Topiramate
Description: phentermine 15mg/ topiramate controlled release (CR) 92mg, oral capsule, once daily, 28 weeks
Study NCT01003834 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Computerized health screening
Description: Behavioral intervention
Study NCT01003834 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Computerized health screening
Description: Behavioral intervention
Study NCT01003834 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Computerized health screening
Description: Behavioral intervention
Study NCT01003834 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Computerized assessment
Description: Behavioral intervention
Study NCT01003834 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Computerized assessment
Description: Behavioral intervention
Study NCT01003834 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Therapist-delivered motivational intervention
Description: Behavioral intervention
Study NCT02808767 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prasugrel
Description: Prasugrel 60 mg loading dose and 10mg/5mg once daily maintenance dose
Study NCT02808767 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ticagrelor
Description: Ticagrelor 180 mg loading dose and 90 mg twice daily maintenance dose
Study NCT00600067 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral placebo capsules, once daily, 28 weeks
Study NCT03606486 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo collection of tumor sample and blood draw
Study NCT03606486 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT01401023 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tigecycline
Description: : Standard treatment doses of oral antibiotics (vancomycin or metronidazole) for CDAD along with IV tigecycline (100 milligram loading dose followed by 50 milligrams every 12 hours) will be given to patients during their hospitalization (usually 7-14 days). Patients well enough to go home will receive only oral therapy.
Study NCT02960204 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Emricasan
Study NCT03706079 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo subcutaneous injection
Study NCT00647881 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paroxetine Hydrochloride Controlled-Release Tablets 25 mg
Description: 25mg, single dose fed
Study NCT00647881 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paxil CR™ Tablets 25 mg
Description: 25mg, single dose fed
Study NCT02796469 — intervention group
Intervention type: DRUG
Intervention: Pentoxifylline
Study NCT03733210 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Leica fluorescence microscope
Description: Fluorescence microscope manufactured by Leica
Study NCT00301847 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sorafenib tosylate
Study NCT05594303 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Autologuos transplantation of bronchial basal cells
Description: Autologuos transplantation of bronchial basal cells
Study NCT03566576 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anlotinib
Description: Anlotinib 8mg p.o. qd in first cohort (3 subjects). 10mg p.o. qd in second cohort (3 subjects). 12mg p.o. qd in third cohort (3 subjects).
Study NCT03606486 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Lavage
Description: Undergo uterine lavage
Study NCT03606486 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pap Smear
Description: Undergo pap smear
Study NCT02404168 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: lamotrigine (brand Lamictal)
Description: an anti-epileptic drug (brand)
Study NCT02404168 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lamotrigine (generic Teva)
Description: an anti-epileptic drug (brand)
Study NCT02881736 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: electroencephalographic,magnetic resonance imaging
Study NCT02881736 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: electroencephalographic,magnetic resonance imaging
Study NCT02307448 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Platelet Rich Plasma
Description: Patients will receive weekly PRP treatments with standard of care.
Study NCT02307448 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Standard of Care
Description: Patients will receive weekly standard of care.
Study NCT04541082 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ONC206
Description: ONC206 is a member of the imipridone class of anti-cancer small molecules that share a unique tri-heterocyclic core chemical structure and target G protein-coupled receptors.
Study NCT03566576 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Description: Pemetrexed 500mg/m2 as a 10-minute intravenous infusion on day 1 of a 21-day cycle.
Study NCT03566576 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Docetaxel 60mg/m2 as a 10-minute intravenous infusion on day 1 of a 21-day cycle.
Study NCT02960204 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT01154439 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cytarabine
Description: Remission induction therapy: by short i.v. infusion on days 1 and 7. Consolidation therapy: by continuous infusion on days 1-5.
Study NCT01154439 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: etoposide
Description: Remission induction therapy: by short i.v. infusion, on days 1-7. Consolidation therapy: by short i.v. infusion, on days 1-5.
Study NCT01154439 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: everolimus
Description: Remission induction therapy: test dose once a day by mouth, on days 1-21 (21 days).~Consolidation therapy: dose as defined by the cohort once a day by mouth, on days 1-10.
Study NCT01154439 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: idarubicin
Description: Consolidation therapy: by short infusion i.c. on days 1, 3 and 5.
Study NCT01154439 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mitoxantrone hydrochloride
Description: Remission induction therapy: by short i.v. infusion on days 1, 3 and 5
Study NCT05115058 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: relex Smile module
Study NCT00495885 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: volinanserin (M100907)
Description: oral, one tablet taken around bedtime
Study NCT00469833 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: insulin glargine
Description: Diabetic subjects will be treated with insulin glargine once daily for 2 months. Subjects will monitor their blood glucose and have their insulin dose adjusted in steps of 4-6 units to achieve a goal of less than or equal to 120 mg/dl for fasting blood glucose.
Study NCT05110573 — intervention group
Intervention type: PROCEDURE
Intervention: pancreatoduodenectomy
Description: Patients included in the cohorts all underwent pancreatoduodenectomy, open or laparoscopic
Study NCT05753514 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ESWT
Description: ESWT
Study NCT03129542 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Midodrine Hydrochloride 10 milligrams
Description: Three doses taken every 8 hours.
Study NCT03129542 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo capsule
Description: Three doses taken every 8 hours.
Study NCT00363311 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dutasteride
Description: Dutasteride 0.5mg
Study NCT00363311 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Matching placebo
Description: Matching placebo
Study NCT03249194 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Direct acting Anti-Viral Therapy using Epclusa or Zepatier
Description: All patients will receive one 'on-call' dose of SOFOSBUVIR/VELPATASVIR (Epclusa, Gilead) immediately prior to transplant and one dose on post-operative Day 1 post-transplant. Patients who develop detectable HCV viremia will be initiated on Direct Acting Anti-viral (DAA) therapy between 2-4 weeks post-transplant. Patients with GT1 will be treated with ELBASVIR/GRAZOPREVIR (Zepatier, Merck) and those with GT2 or 3 will be treated with SOFOSBUVIR/VELPATASVIR (Epclusa, Gilead) based upon donor genotyping results
Study NCT01027858 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Aerobic-based exercise training
Description: Six months of thrice-weekly walking program that will gradually progress in intensity. Each training session will be 60 minutes (10 minutes of warm-up, 40 minutes of training, and 10 minutes of cool-down).
Study NCT01027858 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: CON (control; usual care)
Description: Nutrition education and usual care as prescribed by neurologist
Study NCT02014805 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiotherapy
Description: postoperative conformal radiotherapy for Masaoka stage II-III B type thymoma
Study NCT04364555 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clobetasol Propionate
Description: Klobetasol APL oral gel 0.025% is a topical steroid for rinsing the oral cavity. Manufactured by APL, Sweden.
Study NCT04364555 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo/Klobetasol APL oral gel 0.025%
Description: Placebo/active
Study NCT04364555 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo/placebo
Study NCT00326599 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carboplatin
Description: Given IV
Study NCT00326599 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: carboplatin
Description: Given IV
Study NCT00326599 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cediranib maleate
Description: Given orally
Study NCT00326599 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemcitabine hydrochloride
Description: Given IV
Study NCT00326599 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: gemcitabine hydrochloride
Description: Given IV
Study NCT04273165 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Etravirine Tablets
Description: Daily etravirine BID with 100 or 200 tablets for 4 months
Study NCT01508910 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Auto-CD34+ cells
Description: 10 intramyocardial injections of 0.2 mL per injection site of Auto-CD34+ cells
Study NCT01508910 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo: Diluent used to suspend Auto-CD34+ cells
Description: 10 intramyocardial injections of 0.2 mL per injection site of placebo
Study NCT01508910 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Standard of care
Description: Standard of care for refractory angina
Study NCT02099825 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: d-cycloserine and mifepristone
Description: All participants will receive a one-time only dose of both, d-cycloserine and mifepristone at Session 2
Study NCT02099825 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: d-cycloserine and mifepristone
Description: All participants will receive a one-time only dose of both, d-cycloserine and mifepristone at Session 2
Study NCT02246010 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Lactose- free milk
Description: Lactose- free milk
Study NCT03555877 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribociclib
Description: Ribociclib in addition to endocrine maintenance therapy. Endocrine therapy, at the discretion of the investigator, could have already been started up to 4 weeks before randomization but not later than with first dose of ribociclib.
Study NCT03555877 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Anastrozole
Description: 1mg once daily as indicated in the SmPC
Study NCT03555877 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anastrozole
Description: 1mg once daily as indicated in the SmPC
Study NCT03555877 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Letrozole
Description: 2,5mg once daily as indicated in the SmPC
Study NCT03555877 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Letrozole
Description: 2,5mg once daily as indicated in the SmPC
Study NCT03555877 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Exemestane
Description: 25mg once daily as indicated in the SmPC
Study NCT00495885 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: oral, one tablet taken around bedtime
Study NCT03766971 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: 7 days of Tobacco Cessation
Description: Participants will be randomly assigned to 7 days of tobacco cessation.
Study NCT03766971 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: 21 days of Tobacco Cessation
Description: Participants will be randomly assigned to 21 days of tobacco cessation.
Study NCT03766971 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cannabis
Description: Participants will receive cannabis.
Study NCT01761552 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sugammadex Reversal
Study NCT01761552 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atropine/Neostigmine
Study NCT01037634 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oseltamivir
Description: 3 mg/kg given orally for 5 days for seasonal influenza, 7 days for 2009 H1N1 influenza (in Vietnam only), or 10 days for avian influenza, for children whose renal function is greater than or equal to 30 mL/min/1.73m2
Study NCT02796469 — intervention group
Intervention type: DRUG
Intervention: Corticosteroid
Study NCT03124862 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ARM sensor
Description: Acoustic Monitoring sensor that monitors respiratory rate
Study NCT04273581 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: 100mg/d，qn，for 14 days.
Study NCT04273581 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thalidomide
Description: 100mg/d，qn，for 14 days.
Study NCT03510182 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: transcranial direct current stimulation
Study NCT03192865 — intervention group
Intervention type: PROCEDURE
Intervention: diaphragmatic assessment using ultrasounds.
Description: A diaphragmatic assessment will be performed using ultrasound. This is a pain free assessment. This assessment is commun in our unit after arthroscopic shoulder surgery.
Study NCT02964949 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Edoxaban
Description: Edoxaban will be provided in blister packs with active and placebo tablets maintaining the blind, i.e., one 60 mg active tablet and a 15 mg placebo or one 60 mg active tablet and a 15 mg active tablet. Transition doses of 30 mg + 15 mg edoxaban are provided in 14-tablet blister packs.
Study NCT02964949 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Edoxaban
Description: Edoxaban will be provided in blister packs with active and placebo tablets maintaining the blind, i.e., one 60 mg active tablet and a 15 mg placebo or one 60 mg active tablet and a 15 mg active tablet. Transition doses of 30 mg + 15 mg edoxaban are provided in 14-tablet blister packs.
Study NCT04188301 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: IVM w/ ALB
Description: Participants will be given a single dose of oral IVM (150 µg/kg) plus ALB (400 mg) (IVM/ALB)
Study NCT04188301 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Single dose of IDA
Description: Participants will be given a single dose of oral IVM (150 µg/kg), DEC (6 mg/kg) and ALB (400 mg)
Study NCT04188301 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Three daily doses of IDA
Description: Participants will be given one daily dose for 3 days of oral IVM (150 µg/kg), DEC (6 mg/kg) and ALB (400 mg)
Study NCT01163448 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: High-Dose Single-Fraction Image-Guided Radiotherapy for Men Undergoing Radical Prostatectomy
Description: A baseline DCE-MRI will be obtained prior to the day of radiotherapy treatment. Immediately following the delivery of radiotherapy another DCE-MRI will be performed to assess for perfusion changes in the prostate resulting from irradiation. RP will be completed within 6 weeks (+ 2 weeks) of radiation and the RP specimen will be assessed for radiation treatment effect and other pathologic parameters (including surgical margin status) by a dedicated genitourinary pathologist. Following RP, participants will follow-up with their surgeon every 3 months for one year, with visits alternating between the urologist and the radiation oncologist. After the first year follow-up will occur at 6 month intervals until the patient is 3 years out from surgery.
Study NCT01685073 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zolpidem extended-release
Description: nightly administration of zolpidem extended-release
Study NCT03555877 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Exemestane
Description: 25mg once daily as indicated in the SmPC
Study NCT02217904 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 1 mg islatravir
Description: Single oral dose of 1 mg islatravir administered following ≥8 hour fast
Study NCT03555877 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fulvestrant
Description: (prefilled syringes with fulvestrant 250mg each), 500mg given once a month, with an additional 500mg dose given two weeks after the first dose as indicated in the SmPC
Study NCT03555877 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fulvestrant
Description: (prefilled syringes with fulvestrant 250mg each), 500mg given once a month, with an additional 500mg dose given two weeks after the first dose as indicated in the SmPC
Study NCT01430572 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Everolimus
Description: Starting dose: 5.0 mg by mouth on Days 1 - 5 of Cycle 1. On Day 7 and every cycle-day with an odd number, only everolimus will be administered.~Dose Expansion Phase: Maximum tolerated dose (MTD) from lead in phase.
Study NCT03007121 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Morphine intrathecal
Description: Administration of intrathecal injection of 0.3 mg preservative-free morphine in 3 ml NS
Study NCT03007121 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine + Sufentanil epidural
Description: Continuous epidural infusion of a mixture containing in 1 ml bupivacaine 0,125% and sufentanil 0,4 mcg at 8 ml/h.
Study NCT02796469 — intervention group
Intervention type: DRUG
Intervention: Placebo
Study NCT00606489 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Caldolor
Description: 800 milligrams of intravenous ibuprofen (patients greater 12 years of age) or 10 milligrams/kilograms (patients greater than 12 years; maximum of 400 milligrams) every 6 hours
Study NCT03007121 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Morphine intravenous
Description: Patiernt-controlled i.v. analgesia with morphine
Study NCT03007121 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Morphine intravenous
Description: Patiernt-controlled i.v. analgesia with morphine
Study NCT00671216 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK233705
Description: Subjects will receive 200 (mcg) microgram once daily as a single dose
Study NCT02217904 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 2 mg islatravir
Description: Single oral dose of 2 mg islatravir administered following ≥8 hour fast
Study NCT02217904 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 10 mg islatravir
Description: Single oral dose of 10 mg islatravir administered following ≥8 hour fast
Study NCT02217904 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 30 mg islatravir
Description: Single oral dose of 30 mg islatravir administered following ≥8 hour fast
Study NCT02217904 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0.5 mg islatravir
Description: Single oral dose of 0.5 mg islatravir administered following ≥8 hour fast